InflaRx Raises $150M in Share Offering to Fuel Pipeline
Event summary
- InflaRx priced a $150M underwritten offering of 75M ordinary shares at $2.00 per share.
- Proceeds will fund pipeline activities, working capital, and general corporate purposes.
- New and existing investors participated, including TCGX and Farallon Capital Management.
- The offering is expected to close on May 7, 2026.
- Guggenheim Securities acted as lead bookrunner.
The big picture
InflaRx’s $150M share offering underscores the biopharmaceutical company’s push to strengthen its pipeline, particularly in anti-inflammatory therapeutics targeting the complement system. The participation of large healthcare-focused funds like TCGX and Farallon Capital Management suggests confidence in InflaRx’s long-term potential, despite the challenging capital-raising environment for biotechs. The proceeds will be critical in advancing izicopan and vilobelimab, both of which have shown promise in clinical studies.
What we're watching
- Pipeline Progress
- How InflaRx allocates the $150M to advance its lead programs, izicopan and vilobelimab, will signal its strategic priorities.
- Market Reception
- Whether the new capital stabilizes or boosts InflaRx’s stock price, given the offering price of $2.00 per share.
- Investor Confidence
- The pace at which new investors engage with InflaRx post-offering, reflecting sentiment toward its anti-inflammatory pipeline.
Related topics